( Root (span 1 98)
  ( Nucleus (span 1 15) (rel2par span)
    ( Nucleus (span 1 9) (rel2par span)
      ( Nucleus (span 1 4) (rel2par span)
        ( Nucleus (span 1 2) (rel2par span)
          ( Nucleus (leaf 1) (rel2par span) (text _!Earnings for most of the nation's major pharmaceutical makers are believed to have moved ahead briskly in the third quarter,_!) )
          ( Satellite (leaf 2) (rel2par elaboration-additional) (text _!as companies with newer, big-selling prescription drugs fared especially well._!) )
        )
        ( Satellite (span 3 4) (rel2par antithesis)
          ( Nucleus (leaf 3) (rel2par span) (text _!For the third consecutive quarter, however, most of the companies' revenues were battered by adverse foreign-currency translations_!) )
          ( Satellite (leaf 4) (rel2par result) (text _!as a result of the strong dollar abroad._!) )
        )
      )
      ( Satellite (span 5 9) (rel2par example)
        ( Nucleus (span 5 7) (rel2par span)
          ( Satellite (leaf 5) (rel2par attribution) (text _!Analysts said_!) )
          ( Nucleus (span 6 7) (rel2par span)
            ( Nucleus (leaf 6) (rel2par span) (text _!that Merck & Co., Eli Lilly & Co., Warner-Lambert Co. and the Squibb Corp. unit of Bristol-Myers Squibb Co. all benefited from strong sales of relatively new, higher-priced medicines_!) )
            ( Satellite (leaf 7) (rel2par elaboration-object-attribute-e) (text _!that provide wide profit margins._!) )
          )
        )
        ( Satellite (span 8 9) (rel2par comparison)
          ( Nucleus (leaf 8) (rel2par span) (text _!Less robust earnings at Pfizer Inc. and Upjohn Co. were attributed to those companies' older products,_!) )
          ( Satellite (leaf 9) (rel2par elaboration-object-attribute-e) (text _!many of which face stiffening competition from generic drugs and other medicines._!) )
        )
      )
    )
    ( Satellite (span 10 15) (rel2par explanation-argumentative)
      ( Nucleus (span 10 13) (rel2par span)
        ( Satellite (leaf 10) (rel2par attribution) (text _!Joseph Riccardo, an analyst with Bear, Stearns & Co., said_!) )
        ( Nucleus (span 11 13) (rel2par span)
          ( Nucleus (leaf 11) (rel2par List) (text _!that over the past few years most drug makers have shed their slow-growing businesses_!) )
          ( Nucleus (span 12 13) (rel2par List)
            ( Nucleus (leaf 12) (rel2par span) (text _!and instituted other cost savings,_!) )
            ( Satellite (leaf 13) (rel2par example) (text _!such as consolidating manufacturing plants and administrative staffs._!) )
          )
        )
      )
      ( Satellite (span 14 15) (rel2par consequence-s)
        ( Nucleus (leaf 14) (rel2par span) (text _!As a result, "major new products are having significant impact, even on a company with very large revenues,"_!) )
        ( Satellite (leaf 15) (rel2par attribution) (text _!Mr. Riccardo said._!) )
      )
    )
  )
  ( Satellite (span 16 98) (rel2par elaboration-additional)
    ( Nucleus (span 16 22) (rel2par span)
      ( Nucleus (span 16 17) (rel2par span)
        ( Satellite (leaf 16) (rel2par attribution) (text _!Analysts said_!) )
        ( Nucleus (leaf 17) (rel2par span) (text _!profit for the dozen or so big drug makers, as a group, is estimated to have climbed between 11% and 14%._!) )
      )
      ( Satellite (span 18 22) (rel2par interpretation-s)
        ( Satellite (leaf 18) (rel2par antithesis) (text _!While that's not spectacular,_!) )
        ( Nucleus (span 19 22) (rel2par span)
          ( Satellite (leaf 19) (rel2par attribution) (text _!Neil Sweig, an analyst with Prudential Bache, said_!) )
          ( Nucleus (span 20 22) (rel2par span)
            ( Nucleus (span 20 21) (rel2par span)
              ( Nucleus (leaf 20) (rel2par span) (text _!that the rate of growth will "look especially good_!) )
              ( Satellite (leaf 21) (rel2par comparison) (text _!as compared to other companies_!) )
            )
            ( Satellite (leaf 22) (rel2par condition) (text _!if the economy turns downward."_!) )
          )
        )
      )
    )
    ( Satellite (span 23 98) (rel2par elaboration-set-member)
      ( Nucleus (span 23 33) (rel2par List)
        ( Nucleus (span 23 31) (rel2par span)
          ( Nucleus (span 23 30) (rel2par span)
            ( Nucleus (span 23 26) (rel2par span)
              ( Satellite (leaf 23) (rel2par attribution) (text _!Mr. Sweig estimated_!) )
              ( Nucleus (span 24 26) (rel2par span)
                ( Nucleus (leaf 24) (rel2par span) (text _!that Merck's profit for the quarter rose by about 22%,_!) )
                ( Satellite (span 25 26) (rel2par explanation-argumentative)
                  ( Nucleus (leaf 25) (rel2par span) (text _!propelled by sales of its line-up of fast-growing prescription drugs,_!) )
                  ( Satellite (leaf 26) (rel2par elaboration-set-member-e) (text _!including its anti-cholesterol drug, Mevacor; a high blood pressure medicine, Vasotec; Primaxin, an antibiotic, and Pepcid, an anti-ulcer medication._!) )
                )
              )
            )
            ( Satellite (span 27 30) (rel2par elaboration-additional)
              ( Nucleus (span 27 29) (rel2par span)
                ( Nucleus (span 27 28) (rel2par span)
                  ( Nucleus (leaf 27) (rel2par span) (text _!Profit climbed_!) )
                  ( Satellite (leaf 28) (rel2par concession) (text _!even though Merck's sales were reduced by "one to three percentage points"_!) )
                )
                ( Satellite (leaf 29) (rel2par result) (text _!as a result of the strong dollar,_!) )
              )
              ( Satellite (leaf 30) (rel2par attribution) (text _!Mr. Sweig said._!) )
            )
          )
          ( Satellite (leaf 31) (rel2par elaboration-additional) (text _!In the third quarter of 1988, Merck earned $311.8 million, or 79 cents a share._!) )
        )
        ( Satellite (span 32 33) (rel2par antithesis)
          ( Satellite (leaf 32) (rel2par attribution) (text _!In Rahway, N.J., a Merck spokesman said_!) )
          ( Nucleus (leaf 33) (rel2par span) (text _!the company doesn't make earnings projections._!) )
        )
      )
      ( Nucleus (span 34 44) (rel2par List)
        ( Nucleus (span 34 43) (rel2par span)
          ( Nucleus (span 34 42) (rel2par span)
            ( Nucleus (span 34 40) (rel2par span)
              ( Nucleus (span 34 37) (rel2par span)
                ( Satellite (leaf 34) (rel2par attribution) (text _!Mr. Sweig said_!) )
                ( Nucleus (span 35 37) (rel2par span)
                  ( Satellite (leaf 35) (rel2par attribution) (text _!he estimated_!) )
                  ( Nucleus (span 36 37) (rel2par span)
                    ( Nucleus (leaf 36) (rel2par span) (text _!that Lilly's earnings for the quarter jumped about 20%,_!) )
                    ( Satellite (leaf 37) (rel2par result) (text _!largely because of the performance of its new anti-depressant Prozac._!) )
                  )
                )
              )
              ( Satellite (span 38 40) (rel2par elaboration-additional)
                ( Nucleus (span 38 39) (rel2par Same-Unit)
                  ( Nucleus (leaf 38) (rel2par span) (text _!The drug,_!) )
                  ( Satellite (leaf 39) (rel2par elaboration-additional-e) (text _!introduced last year,_!) )
                )
                ( Nucleus (leaf 40) (rel2par Same-Unit) (text _!is expected to generate sales of about $300 million this year._!) )
              )
            )
            ( Satellite (span 41 42) (rel2par evaluation-s)
              ( Nucleus (leaf 41) (rel2par span) (text _!"It's turning out to be a real blockbuster,"_!) )
              ( Satellite (leaf 42) (rel2par attribution) (text _!Mr. Sweig said._!) )
            )
          )
          ( Satellite (leaf 43) (rel2par elaboration-additional) (text _!In last year's third quarter, Lilly earned $171.4 million, or $1.20 a share._!) )
        )
        ( Satellite (leaf 44) (rel2par antithesis) (text _!In Indianapolis, Lilly declined comment._!) )
      )
      ( Nucleus (span 45 57) (rel2par List)
        ( Nucleus (span 45 47) (rel2par span)
          ( Satellite (leaf 45) (rel2par attribution) (text _!Several analysts said_!) )
          ( Nucleus (span 46 47) (rel2par span)
            ( Nucleus (leaf 46) (rel2par span) (text _!they expected Warner-Lambert's profit also to increase by more than 20% from $87.7 million, or $1.25 a share,_!) )
            ( Satellite (leaf 47) (rel2par elaboration-object-attribute-e) (text _!it reported in the like period last year._!) )
          )
        )
        ( Satellite (span 48 57) (rel2par elaboration-additional)
          ( Nucleus (span 48 50) (rel2par span)
            ( Nucleus (leaf 48) (rel2par span) (text _!The company is praised by analysts_!) )
            ( Satellite (span 49 50) (rel2par reason)
              ( Nucleus (leaf 49) (rel2par List) (text _!for sharply lowering its costs in recent years_!) )
              ( Nucleus (leaf 50) (rel2par List) (text _!and shedding numerous companies with low profit margins._!) )
            )
          )
          ( Satellite (span 51 57) (rel2par elaboration-additional)
            ( Nucleus (span 51 54) (rel2par span)
              ( Nucleus (span 51 52) (rel2par Same-Unit)
                ( Nucleus (leaf 51) (rel2par span) (text _!The company's lean operation,_!) )
                ( Satellite (leaf 52) (rel2par attribution-e) (text _!analysts said,_!) )
              )
              ( Nucleus (span 53 54) (rel2par Same-Unit)
                ( Nucleus (leaf 53) (rel2par span) (text _!allowed sharp-rising sales from its cholesterol drug, Lopid,_!) )
                ( Satellite (leaf 54) (rel2par consequence-s) (text _!to power earnings growth._!) )
              )
            )
            ( Satellite (span 55 57) (rel2par elaboration-additional)
              ( Nucleus (leaf 55) (rel2par span) (text _!Lopid sales are expected to be about $300 million this year, up from $190 million in 1988._!) )
              ( Satellite (span 56 57) (rel2par elaboration-additional)
                ( Satellite (leaf 56) (rel2par attribution) (text _!In Morris Plains, N.J., a spokesman for the company said_!) )
                ( Nucleus (leaf 57) (rel2par span) (text _!the analysts' projections are "in the ballpark."_!) )
              )
            )
          )
        )
      )
      ( Nucleus (span 58 64) (rel2par List)
        ( Nucleus (span 58 63) (rel2par span)
          ( Nucleus (span 58 62) (rel2par span)
            ( Nucleus (span 58 60) (rel2par Same-Unit)
              ( Nucleus (leaf 58) (rel2par span) (text _!Squibb's profit,_!) )
              ( Satellite (span 59 60) (rel2par elaboration-additional-e)
                ( Nucleus (leaf 59) (rel2par span) (text _!estimated by analysts to be about 18% above the $123 million, or $1.25 a share,_!) )
                ( Satellite (leaf 60) (rel2par elaboration-object-attribute-e) (text _!it earned in the third quarter of 1988,_!) )
              )
            )
            ( Nucleus (span 61 62) (rel2par Same-Unit)
              ( Nucleus (leaf 61) (rel2par span) (text _!was the result of especially strong sales of its Capoten drug_!) )
              ( Satellite (leaf 62) (rel2par elaboration-object-attribute-e) (text _!for treating high blood pressure and other heart disease._!) )
            )
          )
          ( Satellite (leaf 63) (rel2par elaboration-additional) (text _!The company was officially merged with Bristol-Myers Co. earlier this month._!) )
        )
        ( Satellite (leaf 64) (rel2par elaboration-additional) (text _!Bristol-Myers declined to comment._!) )
      )
      ( Nucleus (span 65 74) (rel2par List)
        ( Nucleus (span 65 68) (rel2par span)
          ( Nucleus (span 65 66) (rel2par span)
            ( Satellite (leaf 65) (rel2par attribution) (text _!Mr. Riccardo of Bear Stearns said_!) )
            ( Nucleus (leaf 66) (rel2par span) (text _!that Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% are largely because "those companies are really managed well."_!) )
          )
          ( Satellite (span 67 68) (rel2par elaboration-additional)
            ( Nucleus (leaf 67) (rel2par Comparison) (text _!ScheringPlough earned $94.4 million, or 84 cents a share,_!) )
            ( Nucleus (leaf 68) (rel2par Comparison) (text _!while Bristol-Myers earned $232.3 million, or 81 cents a share, in the like period a year earlier._!) )
          )
        )
        ( Satellite (span 69 74) (rel2par elaboration-additional)
          ( Nucleus (span 69 71) (rel2par span)
            ( Satellite (leaf 69) (rel2par attribution) (text _!In Madison, N.J., a spokesman for Schering-Plough said_!) )
            ( Nucleus (span 70 71) (rel2par span)
              ( Nucleus (leaf 70) (rel2par span) (text _!the company has "no problems" with the average estimate by a analysts_!) )
              ( Satellite (leaf 71) (rel2par elaboration-object-attribute-e) (text _!that third-quarter earnings per share rose by about 19%, to $1._!) )
            )
          )
          ( Satellite (span 72 74) (rel2par explanation-argumentative)
            ( Nucleus (span 72 73) (rel2par span)
              ( Nucleus (leaf 72) (rel2par span) (text _!The company expects to achieve the 20% increase in full-year earnings per share,_!) )
              ( Satellite (leaf 73) (rel2par comparison) (text _!as it projected in the spring,_!) )
            )
            ( Satellite (leaf 74) (rel2par attribution) (text _!the spokesman said._!) )
          )
        )
      )
      ( Nucleus (span 75 85) (rel2par List)
        ( Nucleus (span 75 84) (rel2par span)
          ( Nucleus (span 75 83) (rel2par span)
            ( Nucleus (span 75 81) (rel2par span)
              ( Nucleus (span 75 77) (rel2par span)
                ( Satellite (leaf 75) (rel2par attribution) (text _!Meanwhile, analysts said_!) )
                ( Nucleus (span 76 77) (rel2par span)
                  ( Nucleus (leaf 76) (rel2par span) (text _!Pfizer's recent string of lackluster quarterly performances continued,_!) )
                  ( Satellite (leaf 77) (rel2par elaboration-additional) (text _!as earnings in the quarter were expected to decline by about 5%._!) )
                )
              )
              ( Satellite (span 78 81) (rel2par example)
                ( Nucleus (span 78 80) (rel2par span)
                  ( Nucleus (span 78 79) (rel2par Same-Unit)
                    ( Nucleus (leaf 78) (rel2par span) (text _!Sales of Pfizer's important drugs, Feldene_!) )
                    ( Satellite (leaf 79) (rel2par elaboration-additional-e) (text _!for treating arthritis,_!) )
                  )
                  ( Nucleus (leaf 80) (rel2par Same-Unit) (text _!and Procardia, a heart medicine, have shrunk_!) )
                )
                ( Satellite (leaf 81) (rel2par explanation-argumentative) (text _!because of increased competition._!) )
              )
            )
            ( Satellite (span 82 83) (rel2par elaboration-additional)
              ( Nucleus (leaf 82) (rel2par span) (text _!"The (strong) dollar hurt Pfizer a lot, too,"_!) )
              ( Satellite (leaf 83) (rel2par attribution) (text _!Mr. Sweig said._!) )
            )
          )
          ( Satellite (leaf 84) (rel2par elaboration-additional) (text _!In the third quarter last year, Pfizer earned $216.8 million, or $1.29 a share._!) )
        )
        ( Satellite (leaf 85) (rel2par elaboration-additional) (text _!In New York, the company declined comment._!) )
      )
      ( Nucleus (span 86 98) (rel2par List)
        ( Nucleus (span 86 97) (rel2par span)
          ( Nucleus (span 86 89) (rel2par span)
            ( Satellite (leaf 86) (rel2par attribution) (text _!Analysts said_!) )
            ( Nucleus (span 87 89) (rel2par span)
              ( Nucleus (leaf 87) (rel2par span) (text _!they expected Upjohn's profit to be flat or rise by only about 2% to 4%_!) )
              ( Satellite (span 88 89) (rel2par comparison)
                ( Nucleus (leaf 88) (rel2par span) (text _!as compared with $89.6 million, or 49 cents a share,_!) )
                ( Satellite (leaf 89) (rel2par elaboration-object-attribute-e) (text _!it earned a year ago._!) )
              )
            )
          )
          ( Satellite (span 90 97) (rel2par explanation-argumentative)
            ( Nucleus (span 90 93) (rel2par List)
              ( Nucleus (leaf 90) (rel2par span) (text _!Upjohn's biggest-selling drugs are Xanax, a tranquilizer, and Halcion, a sedative._!) )
              ( Satellite (span 91 93) (rel2par elaboration-additional)
                ( Nucleus (span 91 92) (rel2par Same-Unit)
                  ( Nucleus (leaf 91) (rel2par span) (text _!Sales of both drugs have been hurt by new state laws_!) )
                  ( Satellite (leaf 92) (rel2par elaboration-object-attribute-e) (text _!restricting the prescriptions of certain tranquilizing medicines_!) )
                )
                ( Nucleus (leaf 93) (rel2par Same-Unit) (text _!and adverse publicity about the excessive use of the drugs._!) )
              )
            )
            ( Nucleus (span 94 97) (rel2par List)
              ( Nucleus (span 94 96) (rel2par span)
                ( Satellite (span 94 95) (rel2par concession)
                  ( Nucleus (leaf 94) (rel2par span) (text _!Also, the company's hair-growing drug, Rogaine, is selling well_!) )
                  ( Satellite (leaf 95) (rel2par elaboration-additional-e) (text _!-- at about $125 million for the year,_!) )
                )
                ( Nucleus (leaf 96) (rel2par span) (text _!but the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising,_!) )
              )
              ( Satellite (leaf 97) (rel2par attribution) (text _!analysts said._!) )
            )
          )
        )
        ( Satellite (leaf 98) (rel2par elaboration-additional) (text _!In Kalamazoo, Mich., Upjohn declined comment._!) )
      )
    )
  )
)
